ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Axitinib

Also written as “AG-013736”, “axitinib” and “OTX-TKI”.

Its studies are mostly in Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Macular Degeneration · Neoplasms · Carcinoma, led by 6 companies.

Drug pageAxitinib: every studyMany companies study it; this page follows only the 45 they lead. All 139 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 7, 200745 company-led studies, 4 open or runningNext primary completion: Jan 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only360 open or runningphase 3since May 7, 2007Oct 9, 2003none ahead
Ocular Therapeutixits history only54 open or runningphase 3since Jan 12, 2024Jun 1, 2018Jan 8, 2027phase 3 · NCT06495918
Arog Pharmaceuticalsits history only10 open or runningphase 2since Oct 6, 2006Oct 6, 2006none ahead
Merckits history only10 open or runningphase 3since Jul 29, 2016Jul 29, 2016none ahead
SFJ Pharma Ltd. IIits history only10 open or runningphase 3since May 11, 2012May 11, 2012none ahead
Strata Oncology10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Fortrea, Gilead Sciences and SFJ Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Strata Oncology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2021First study: phase 2 study in NeoplasmsFirst studyNCT05097599 · 11 enrolled · United States

TargetBeta

“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
chiauranibruleChipscreen Biosciencesphase 315

Studies

The one study Strata Oncology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05097599Neoplasms · United States2TerminatedJun 12, 202411

How it is read

Names in the registry

  • “AG-013736”, 23 entries
  • “axitinib”, 13 entries
  • “OTX-TKI”, 8 entries
  • “Axitinib (AG-013736)”, 8 entries
  • “AG-013736 (axitinib)”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.